Status:
ACTIVE_NOT_RECRUITING
Study of CYR-064 Versus Placebo in Patients.
Lead Sponsor:
Cyrano Therapeutics, Inc.
Conditions:
Hyposmia
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.
Detailed Description
The purpose of this study is to determine the safety and effectiveness of CYR-064 in a randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR064. The study w...
Eligibility Criteria
Inclusion
- Able to provide written informed consent.
- Male or female 18-70 years of age.
- Endoscopy of the nasal cavity showing no structural or pathologic issues leading to hyposmia (nasal polyps, sinusitis, infection, etc.) that in the opinion of the Investigator, believes would hinder the delivery of study drug to the olfactory receptors.
- CT scan of the nasal cavity after the onset of hyposmia (within prior 2 years) prior to Baseline showing no structural or pathologic issue leading to hyposmia that in the opinion of the Investigator, believes would hinder the delivery of study drug to the olfactory receptors.
- Willing and able to self-administer the study drug, follow the study drug administration instructions, comply with study procedures, and participate in the scheduled study visits specified in this protocol.
Exclusion
- History of traumatic brain injury, Parkinson's disease, early dementia, Alzheimer's disease, or any other condition in which hyposmia is not expected to improve in the opinion of the Investigator, such as history of congenital or idiopathic hyposmia or a surgical procedure that led to hyposmia.
- History of surgery that led to hyposmia.
- Concomitant Medical Conditions
- Current symptoms or signs of an acute respiratory viral illness at Screening or Baseline.
- Chronic viral infection or immunodeficiency condition (e.g., medical history of human immunodeficiency virus) based on medical records.
- Any active malignancy.
- Any concomitant medical condition that in the opinion of the Investigator, compromises patient safety or compliance with the study protocol or collected data.
- History of moderate to severe Substance Use Disorder within the past 3 years as assessed by the Investigator.
- History of persistent chronic sinusitis without polyps or chronic sinusitis with polyps.
- Use or planned use of tobacco or nicotine-containing products, including smoking, smokeless tobacco, e-cigarettes, or nicotine replacement products within 3 months prior to Screening through EOS.
- Unwilling or unable to discontinue current or planned use of over the counter or prescription medication administered intranasally, with the exception of nasal saline.
- Use or planned use of another investigational drug within 4 weeks prior to Screening through Follow-Up.
- Receiving any concomitant medication/therapy that would, in the opinion of the Investigator, compromise patient safety or compliance with the study protocol or collected data.
- General Exclusions Any female who is pregnant, planning to become pregnant during the study, or who is lactating.
- Vulnerable patients. Any condition or abnormality (including clinical laboratory, physical examination, or vital sign abnormalities), current or past, that, in the opinion of the Investigator, would compromise the efficacy evaluation, safety of the patient, or would interfere with or complicate study procedures or assessments.
Key Trial Info
Start Date :
September 26 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06019000
Start Date
September 26 2023
End Date
October 31 2025
Last Update
April 27 2025
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Colorado ENT & Allergy
Colorado Springs, Colorado, United States, 80923
2
ENTAAFL
Boca Raton, Florida, United States, 33487
3
ENTAAFL
Plantation, Florida, United States, 33324
4
ENTAAFL
Port Saint Lucie, Florida, United States, 34952